Roche attempt to retool arthritis drug for coronavirus pneumonia fails trial
In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra RoActemra.
The Covacta study did not identify any new safety signals for Actemra RoActemra.
Further analysis of the trial results is needed to fully understand the data.
The results will be submitted for publication in a peer-reviewed journal. ■